|
 News |
 |
-
Dec. 7, 2006 Chidamide (Lab Code CS055), a novel HDAC inhibiter for cancer treatment, IND has been approved by SFDA for phase I trial.
- Oct. 2006 Shenzhen Chipscreen Biosciences signs out-license agreement for Chidamide, an investigational cancer compound currently in IND process with San Diego-based HUYA Bioscience for worldwide rights outside China in October 2006. Chipscreen Biosciences will initiate Phase I clinical trials in China upon receiving IND approval from SFDA. HUYA plans to file Investigational New Drug application and commence clinical trials of Chidamide in the United States and Europe.
-
Oct. 20-21, 2006 Dr. Lu was invited to speak at the 3rd Drug Evaluation Conference subjected on the strategy of innovative drug in R&D and evaluation in Beijing. This conference is sponsored by Center for Drug Evaluation of SFDA, which is the highest state organization in charge of drug evaluation. There are about 500 representatives from pharmaceutical manufacturing enterprises and research organizations at home and abroad take part in this meeting.
-
Sept. 17-18, 2006 Dr. Lu is invited to speak at the Fifth Dean and Director Symposium of Chinese Pharmaceutical R & D Institutes in Jinan, Shandong Province on the keynote regarding Drug Discovery and Technique Innovation. Mr. Mingxue Wang, the director of China Association for Pharmaceuticals and Medical Devices Technology Exchange (CPDE) and Mr. Minghai Lu, the secretary-general of CPDE commence the conference. Lead of CPDE, lead of Shandong FDA, lead of Shandong Commerce Group and lead of Shandong Institute of Pharmaceutical Industry attend this meeting and give attendees a speech. In the meeting, Mr. Zhi Yang, section chief of Life Sciences Centre of Ministry of S&T of P.R.C. introduced “Eleven-Five-Year” BioMedicine Technology Development plans. Professor Keliang Liu, Director, Institute of Pharmacology & Toxicology of AMMS, Professor Xiaoliang Wang, Director, Institute of Materia Medica of Chinese Academy of Medical Sciences and Dr. Xian-Ping Lu, President & CSO, Chipscreen Biosciences, Ltd. give invited presentation in the meeting, and get well resound by attendees.
-
Sept 2, 2006 Dr. Xian-Ping Lu, the President and CSO of Shenzhen Chipscreen Bioscience, was invited to attend “Nobel Linus Pauling – Hkbio Mini Symposium” in HKSP. This meeting’s goal is to build a bridge between academia and industry and between USA and HK China.
-
July, 2006, Roche R&D Center China (RRDCC), the fifth fully integrated global R&D Center for Roche signs a two-year research service agreement with Shenzhen Chipscreen Biosciences Ltd, a leading China-based life sciences company specialized in small molecule drug discovery and development. Chipscreen will use its in-house high-through screening and proprietary chemical genomics-based discovery platform to screen and evaluate in early stage of drug discovery on series of compounds provided by RRDCC.
- July, 2006 Shenzhen Chipscreen Bioscience Ltd as a Chinese spotlight drug discovery company reported by Time Asia Magazine, the article named “ The Birth and Rebirth of Shenzhen”. Click the original article to get the details. .
-
Jun. 15, 2006 Mr. Dinghuan Shi, counselor of State Department and formal secretary-general of Ministry of Sciences and Technology of People’s Republic of China, and Mr. Chunmin Hao, Director of Shenzhen S&T expert committee visited Shenzhen Chipscreen Biosciences Ltd. CEO of Chipscreen, Dr. Xian-Ping Lu, accompanied them a facility tour and presented company’s stage progress in innovative drug discovery and development efforts. Mr. Shi and Mr. Hao were excited for the progress and expressed their strong support for Chipscreen’s continuing effort to bring innovative medicines into markets.
- May 21-24, 2006 Dr. Xian-Ping Lu, CEO & CSO of Shenzhen Chipscreen was invited to attend “Impact China II- Pharmaceutical R&D Global Summit” in Shangri-la Hotel in Beijing. This conference’s target is provides a gateway to the World’s Fastest Growing Pharmaceutical Market. Dr. Lu gave a speech named “Can Chinese Biotechs Offer Modern Drug Discovery?” The Presentation discussed Chipscreen Biosciences’ experiences as the leading drug discovery in China and its role in the global pharmaceutical arena.
-
April 24-26, 2006 Dr. Xian-Ping Lu, CEO & CSO of Shenzhen Chipscreen was invited to attend “IBC Drug Discovery and Development Summit” in Tokyo and gave a speech. This conference is a groundbreaking, international conference and exhibition for attendees from USA, Europe, Japan and Asia-Pacific to discuss global partnerships, emerging Asian markets and innovative R&D strategies……. Dr. Lu’s presentation named “Pathway profiling for Lead Optimization and Selection in Early Evaluation of Drug Discovery and Development of NCE’s”was well received by the attendees.
-
March 13-15, 2006 Dr. Xian-Ping Lu, CEO & CSO of Shenzhen Chipscreen was invited to attend “HBM Mountain Retreat” in St. Moritz, Switzerland. This conference provides a platform for industry leaders of private and public biotech, pharma and medtech companies to exchange views in an informal environment.
- Mar.03, 2006 Patent Number ZL 03140230.5, Named “Novel noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity”( Cover CS088) granted in China.
- Feb.16, 2006 Patent Number ZL 03126974.5, Named “Substituted Arylalcanoic Acid Derivatives as PPAR Pan Agonists with Potent Antihyperglycemic and Antihyperlipidemic Activity”( Cover CS038, Chiglitazar) granted in China.
- Jan. 20, 2006 Chipscreen together with Burrill & Company, Shenzhen S&T expert committee successfully host the China Life Sciences Partnering forum at Shenzhen Wuzhou guest House on Jan. 20, 2006
-
Dec. 2005, Chidamide, a novel HDAC inhibitor for cancer treatment, filed IND in China, we expect to get the clinical trial permit in the Q2.
-
Nov. 2005 Chiglitazar, an anti type II diabetes new drug was successfully passed the phase I and entered phase II, present goes smoothly.
- Sep. 06, 2005 Chipscreen was highlighted as Chinese leap ahead Biotechnical company published on Aug. 22/29, 2005 Business Week. They also quoted Dr. Xian-Ping Lu’s viewpoint for the current drug discovery in China . Please link for the details.
- Jul. 29, 2005 Chipscreen was successfully passed the examination of the graveness item “Anti type II diabetes New Drug Discovery” by Department of S&T of Guangdong Province.
-
Jun. 18, 2005 Dr. Xian-Ping Lu was invited to present at “The Third SAPA-GP Annual Conference” in Pennsylvania USA. In his presentation “Modern Drug Discovery and Development Efforts by Chinese Biopharmaceutical Industry”, Dr. Lu introduced the business model and R&D progress of Shenzhen Chipscreen to the attendees. The full texts PPT fptiit ,sicankdis ile on http://www.sapa-gp.org.
-
Jun. 10, 2005 The Chinese SFDA granted Clinical Trial Permit (CTP) to Chipscreen for anti type II diabetes drug Chiglitazar. This is the first CTP and major milestone in Chipscreen’s history.
-
Jun. 6-8, 2005 Dr. Xian-Ping Lu, CEO & CSO of Shenzhen Chipscreen was invited to attend “IBC’S Sixth international Conference on Evaluating Percilnical Drug Safety” in Boston and gave a speech. This conference’s target is early efficacy assessment using predictive methods to reduce efficacy-related attrition, improve preclinical decision-making and expedite clinical trials. Dr. Lu’s presentation was well received by the attendees.
- May 18, 2005 Mr. Heli Hu, Director general of Science and Technology Leading Group Office of the state Council of People’s republic of China and the principal of Shenzhen Bureau of Science Technology & Information, visited Shenzhen Chipscreen Biosciences, Ltd. Dr. Xian- Ping Lu, President & CSO of Chipscreen accompany Mr. Hu looked around the company and reported the company’s R&D progress. Mr. Hu plenary affirmed Chipscreen’s Integrated Drug Discovery Platform and interested in our Computer Aided Drug Design. Meanwhile, Mr. Hu also inquired us the difficulties. He encouraged and highly appraised Chipscreen’s progress and achievements.
- Apr. 29, 2005 An enlarged meeting by SFDA celebrate in Beijing for Chipscreen’s novel drug, an anti type II diabetes chemical medicine—Chiglitazar. The meeting involved the minister of Department V of Center for Drug Evaluation, item principal, expert of Center for Drug Evaluation and 9 experts in the area of basic, preparation, synthesize, pre-clinic and clinic. Chipscreen’s five R&D leader and two experts of the Academy of Military Medical Sciences also take part in the meeting. In the whole day’s meeting, all the experts heard the Chiglitazar’s R&D holistic train of thoughts, and discussed the concerned problems. This meeting imaged manage and guidance by SFDA, company of R&D
|
|
